Anteris Technologies (AVR) announced that the first patients in the United States have been enrolled and successfully treated in the DurAVR Transcatheter Heart Valve global pivotal trial for patients with severe calcific aortic stenosis. The procedures were performed by Azeem Latib, M.D. at Montefiore Medical Center, New York, United States.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AVR:
- Anteris Ends v2vmedtech Development Agreement, Limits Exposure
- Anteris Technologies secures CMS reimbursement for trial site activation
- Anteris Technologies Signs Major Brooklyn Park Facility Lease
- Anteris Technologies participates in a conference call with Cantor Fitzgerald
- AVR Upcoming Earnings Report: What to Expect?